Safety evaluation of Dengzhanxixin injection in 986 elderly inpatients
10.3760/cma.j.issn.0254-9026.2009.09.004
- VernacularTitle:986例老年住院患者使用灯盏细辛注射液的安全性评价
- Author:
Liwei JI
;
Bing ZHOU
;
Yatong ZHANG
;
Jun ZHANG
;
Xin LIN
;
Qian NI
;
Xin HU
;
Chunhua SUN
- Publication Type:Journal Article
- Keywords:
Erigeron breviscapus;
Drug evaluation
- From:
Chinese Journal of Geriatrics
2009;28(9):715-718
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the rationality and safety of dengzhanxixin injection used in elderly inpatients. Methods The clinical data of 986 inpatients including 620 males and 366 females were collected, and questionnaires containing age, sex, discharge diagnosis, symptoms, drug dosage, course of treatment, laboratory examination, adverse drug reaction and drug effect were analyzed. Results For the 986 cases, the average age was(74.3±7.5)years. The average dose of dengzhanxixin injection was (38.2±4.4) ml, once daily by intravenous drip, and the average period of treatment was (10.8±5.2) days. The adverse reaction rate was 0.81%. The levels of blood glucose and hemoglobin were decreased after treatment(t orμ=1226.5,2620.0, both P<0.05), but there were no statistical differences in the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN) and white blood cell count (WBC) before and after treatment (t or μ=122.5, 405.0, 513.5, 996.5, 956.5, all P>0.05). Conclusions It is safe to use dengzhanxixin injection according to the medication description for elderly inpatients.
